Budesonide/formoterol maintenance and reliever therapy in Chinese patients with asthma

Chinese Medical Journal

Volumn 125, Issue 17, 2012, Pages 2994-3001

  Lin Dr , Jiang tao ^a   Chen, Ping ^b   Zhou, Xin ^c   Sun, Tie ying ^d   Xie, Can mao ^e   Xiu, Qing yu ^f   Yao, Wan zhen ^g   Yang, Lan ^h   Yin, Kai sheng ⁱ   Zhang, Yong ming ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^c SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^d BEIJING HOSPITAL   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f SECOND MILITARY MEDICAL UNIVERSITY   (China)

^g PEKING UNIVERSITY THIRD HOSPITAL   (China)

^h THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

ⁱ Jiangsu Provincial Hospital   (China)

Author keywords

Asthma; Budesonide formoterol; Exacerbation; Salmeterol fluticasone

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; DISKUS; FLUTICASONE PROPIONATE PLUS SALMETEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; TERBUTALINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HOARSENESS; HUMAN; LUNG FUNCTION; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PEAK EXPIRATORY FLOW; POST HOC ANALYSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SLEEP AROUSAL DISORDER; SPIROMETRY; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; ASTHMA; BUDESONIDE; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED;

EID: 84866085590     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2012.17.006     Document Type: Article

References (20)

1. Asthma Group in Respiratory Disease Branch of China Medical Association. Guidelines for Prevention and Treatment of Asthma. Chin J Tuberc Respir Dis (Chin) 2008; 31: 177-185.
2. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191.
3. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations in asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337: 1405-1411.
4. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
5. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004; 170: 836-844.
6. Global strategy for the diagnosis, management, and revention of chronic obstructive pulmonary disease (updated 2009). (Accessed September 20, 2011 at: http://www.ginasthma.com)
7. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-1418.
8. Rabe KF, Pizzichini E, Ställberg B, Romero S, Balanzat AM, Atienza T, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129: 246-256.
9. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
10. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006; 368: 744-753.
11. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martínez-Jimenez NE, et al. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61: 725-736.
12. Vogelmeier C, D'Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, et al. Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26: 819-828.
13. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007; 101: 2437-2446.
14. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
15. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Resp J 1999; 14: 902-907.
16. Juniper EF, Stahl E, O'Byrne PM. Minimal important difference for the Asthma Control Questionnaire. Am J Respir Crit Care Med 2001; 163 (5 Pt 2) Suppl: A642.
17. O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW; START Investigators Group. Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med 2009; 179: 19-24.
18. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180: 59-99.
19. Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32: 545-554.
20. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, Sears MR, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol 2010; 125: 600-608.